Safety and Efficacy of the Vibrant Soundbridge (VSB) for Mixed and Conductive Hearing Losses (VSBRW)

September 10, 2019 updated by: Med-El Corporation

Clinical Trial of the Vibrant Soundbridge as a Treatment for Conductive and Mixed Hearing Losses, Using Direct Round Window Cochlear Stimulation.

The purpose of this investigation is to collect feasibility data to assess the safety and efficacy of the Vibrant Soundbridge (VSB), a medical device designed to provide benefit in aided hearing thresholds, speech perception and sound quality to certain individuals with hearing loss with minimal changes in residual hearing. The VSB is currently indicated for adults with moderate-to-severe sensorineural hearing loss. Under the present investigation, adults with conductive and mixed hearing losses who are not successful users of traditional amplification will be assessed.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Los Angeles, California, United States, 90057
        • House Ear Institute
      • San Jose, California, United States, 95124-3910
        • Jennifer Maw, MD
    • Florida
      • Miami, Florida, United States, 33136
        • University of Miami Ear Institute
      • Sarasota, Florida, United States, 34239
        • Silverstein Institute
    • Illinois
      • Hinsdale, Illinois, United States, 60521
        • Ear Institute of Chicago
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • University of Kansas Medical Center
    • Missouri
      • Kansas City, Missouri, United States, 64111
        • Midwest Ear Institute
    • New York
      • Slingerlands, New York, United States, 12159
        • Capitol Region Ear Institute
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27514
        • University of North Carolina Hospital
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15212
        • Pittsburgh Ear Associates
    • Texas
      • Dallas, Texas, United States, 75390
        • University of Texas Southwestern Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults, 18 years of age or older at time of implantation
  • English as the primary language
  • Appropriate motivation and expectation levels
  • Geographically and physically able to return to the investigational center for scheduled evaluations and follow-up appointments.
  • At least a 28-day unsuccessful hearing aid trial (within the past 24 months prior to enrolment).
  • Persons who after being informed that a different hearing aid than the one they currently have may provide improved hearing, still request an implant.
  • Ability to undergo general anesthesia
  • Audiological tests suggest either a conductive or mixed hearing loss. The non-implanted ear may fall outside these criteria; however, threshold levels may not be worse than severe sloping to profound.
  • Conductive Hearing Loss
  • Pure-tone bone-conduction threshold levels in the ear to be implanted shall fall at or within the levels stated below. There should be an air-bone gap of 15 dB HL or more at three or more of the frequencies 500, 1000, 1500, 2000, 3000, and 4000 Hz. Pure-tone air-conduction levels should indicate the presence of at least a moderate hearing loss of at least 41 dB HL. Air conduction levels are not limited on the upper end.
  • Upper Limits of Bone Conduction Thresholds for Conductive Hearing Loss Frequency (kHz) 0.5 1.0 1.5 2.0 3.0 4.0 Bone Conduction upper limit (dBHL) <25 <25 <25 <25 <25 <25
  • Mixed Hearing Loss
  • Pure-tone bone conduction threshold levels in the ear to be implanted shall fall at or within the levels stated below. There should be an air-bone gap of 15 dB HL or more at three or more of the frequencies 500, 1000, 1500, 2000, 3000, and 4000 Hz. Bone conduction thresholds at least three of the frequencies should be 26 dB or greater. Pure-tone air-conduction thresholds should be, on average, at least moderately impaired of 41 dB or greater. Air-conduction levels are not limited on the upper end.
  • Lower and Upper Limits of Bone Conduction Thresholds for Mixed Hearing Loss Frequency (kHz) 0.5 1.0 1.5 2.0 3.0 4.0 Bone Conduction lower limit (dBHL) 0 0 0 0 0 0 Bone Conduction upper limit (dBHL) 45 50 55 65 65 65
  • Good potential for aided speech recognition as indicated by a pre-operative monosyllabic word score of > 30% in the ear to be implanted as measured under headphones at 40 dB SL or at MCL
  • Hearing aid trial with appropriately fitted hearing aids of at least 28 days duration within the past 24 months, unless the subject is unable to wear hearing aids for medical reasons
  • Most recent audiometric data, if available, judged to be of good test-retest reliability.

Exclusion Criteria:

  • Hearing loss of purely sensorineural origin
  • Retrocochlear or central auditory disorders
  • Active middle ear infection
  • Tympanic membrane perforation, ears with previously reconstructed tympanic membranes may be included
  • Bone-conduction thresholds in the ear to be implanted that have demonstrated a recent fluctuation at two or more frequencies of 15 dB in either direction in the last 6 months, as demonstrated by serial audiograms.
  • History of post-adolescent, inner-ear disorders, such as vertigo or labyrinthitis
  • Chronic or non-revisable vestibular or balance disorders
  • Middle ear infections not responsive to medical treatment
  • Skin or scalp conditions that may preclude attachment of the Audio Processor or that may interfere with the use of the Audio Processor
  • Chronic pain in or around the head
  • Current or previous use of an active hearing implant in either ear.
  • Any known physical, psychological, or emotional disorder that may interfere with the completion of scheduled follow-up evaluations
  • Developmental delays or organic brain dysfunction

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Implanted
Implanted with Vibrant Soundbridge
Mixed and conductive hearing loss using round window stimulation
Other Names:
  • VSB
  • VSB RW
  • RW VSB
  • Round Window Stimulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Speech Perception in Quiet (Monosyllables) in Patients Implanted With Vibrant Soundbridge
Time Frame: 6 months post initial activation
Percent correct on words in quiet at the preoperative interval compared to 6 month post operative interval.
6 months post initial activation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Functional Gain Compared to Preoperative Unaided Condition in Patients Implanted With Vibrant Soundbridge.
Time Frame: 6 months post initial activation
Auditory thresholds in the soundfield at the preoperative interval compared to the 6 month postoperative interval.
6 months post initial activation
Speech Perception in Noise (HINT Sentences) in Patients Implanted With Vibrant Soundbridge.
Time Frame: 6 months post initial activation
Signal to Noise Ratio for sentences at the preoperative interval compared to the 6 month interval.
6 months post initial activation
Residual Hearing in Patients Implanted With Vibrant Soundbridge
Time Frame: 10 months post initial activation
Unaided hearing thresholds measured at the 10 month interval compared to the preoperative interval in order to assess any changes
10 months post initial activation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: David Foyt, MD, Capital Region Ear Institute
  • Principal Investigator: Jose Fayad, MD, House Ear Institute
  • Principal Investigator: Jennifer Maw, MD, Jennifer Maw, MD
  • Principal Investigator: Robert Cullen, MD, Midwest Ear Institute
  • Principal Investigator: Douglas Chen, MD, Pittsburgh Ear Associates
  • Principal Investigator: Hinrich Staecker, MD, PhD, University of Kansas Medical Center
  • Principal Investigator: Craig Buchman, MD, University of North Carolina Hospital
  • Principal Investigator: Richard Wiet, MD, Ear Institute of Chicago

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2007

Primary Completion (ACTUAL)

March 1, 2014

Study Completion (ACTUAL)

March 1, 2014

Study Registration Dates

First Submitted

September 5, 2008

First Submitted That Met QC Criteria

September 5, 2008

First Posted (ESTIMATE)

September 8, 2008

Study Record Updates

Last Update Posted (ACTUAL)

September 25, 2019

Last Update Submitted That Met QC Criteria

September 10, 2019

Last Verified

September 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hearing Loss

Clinical Trials on Vibrant Soundbridge

Subscribe